Faron Set To Fly As Bexmarilimab Shows Promise
IO Candidate Offers Unique Mode Of Action
Data have shown that the Finnish firm's bexmarilimab has the potential to be the first macrophage immune checkpoint therapy and big pharma are getting interested in a licensing deal.
